ALKS:NASDAQ
Alkermes Plc
43,96 $
arrow_upward
+1,30%(+0,57) 1D
21 սեպ, 12:47:58 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
44,27 $
High
44,79 $
Low
43,11 $
Mkt. cap
7,38 մլրդ
Avg. vol.
1,56 մլն
Volume
1,47 մլն
P/E ratio
114,21
52-wk high
55,67 $
52-wk low
26,99 $
EPS
0,38 $
Beta
0,27
Shares outstanding
167,76 մլն
No. of employees
2 հզր
Open
44,27 $
High
44,79 $
Low
43,11 $
Mkt. cap
7,38 մլրդ
Avg. vol.
1,56 մլն
Volume
1,47 մլն
P/E ratio
114,21
52-wk high
55,67 $
52-wk low
26,99 $
EPS
0,38 $
Beta
0,27
Shares outstanding
167,76 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
GuruFocus
·
8 րոպե առաջ
ALKS Reiterates by Needham -- Price Target Maintained at $62.00
Investing.com
·
1 ժամ առաջ
TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data
Kalkine Media
·
2 ժամ առաջ
Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment
Investor's Business Daily
·
3 ժամ առաջ
What This Biotech Learned From Narcolepsy And Took To ADHD
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2,05 հզր
Founded1987
Headquarters-
Sector-
Websitealkermes.com